| 张 蝶,高雅茹,刘 丽.PD-L1/PD-1在三阴性乳腺癌中的研究进展[J].肿瘤学杂志,2019,25(11):947-951. |
| PD-L1/PD-1在三阴性乳腺癌中的研究进展 |
| Advances on PD-1/PD-L1 in Triple-Negative Breast Cancer |
| 投稿时间：2019-01-07 |
| DOI：10.11735/j.issn.1671-170X.2019.11.B004 |
|
 |
| 中文关键词: 三阴性乳腺癌 PD-1 PD-L1 免疫疗法 |
| 英文关键词:triple negative breast cancer PD-1 PD-L1 immunotherapy |
| 基金项目:国家自然科学基金（81703882） |
|
| 摘要点击次数: 1306 |
| 全文下载次数: 312 |
| 中文摘要: |
| 摘 要：程序性死亡受体1（PD-1）及其配体（PD-L1）的免疫检查点阻滞疗法在多种实体瘤的治疗中疗效显著。三阴性乳腺癌以侵袭力强、预后差、复发风险高为临床特点。由于基因组不稳定和较高的突变率，三阴性乳腺癌的新抗原和免疫原性增加较快，目前缺乏明确的治疗靶点。与其他亚型的乳腺癌相比，PD-L1在三阴性乳腺癌中的表达偏高，这也预示着PD-1、PD-L1可能是治疗三阴性乳腺癌的潜在靶点。全文总结三阴性乳腺癌中的PD-1/PD-L1的调控机制和相关抗癌药物的临床研究，以期为治疗三阴性乳腺癌提供新的方法与思路。 |
| 英文摘要: |
| Abstract：Immune checkpoint blockade therapies(ICBTs) targeting programmed cell death-1(PD-1) and its ligand programmed death ligand-1(PD-L1) have shown great therapeutic efficacy in a variety of solid malignant tumors. Triple negative breast cancer(TNBC) is characterized by strong invasiveness，poor prognosis and high risk of recurrence. Due to genomic instability and high mutation rate with emerging new antigens， there have been no clear targets for TNBC therapy. The expression of PD-L1 in TNBC is higher than other subtypes of breast cancer，indicating that PD-1，PD-L1 might be a potential target for the treatment of TNBC. This article summarizes the regulatory mechanisms of PD-1 and PD-L1 in TNBC and clinical trials of related drugs，to provide insights on new methods and ideas for the treatment of TNBC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |